Trends and Advancements in Drug Delivery: What is the "perfect" method of drug delivery?

Main Article Content

Stephen Bevan Shrewsbury

Abstract

In this imperfect world, given that humans often need to treat or prevent disease by delivering medicine to the target cells earlier and for longer than previously possible, certain optimum requirements should be met. Treatment, or prevention, by a therapeutic molecule should be delivered at the right time, at the right dose, to the right target cell, by the safest, most convenient, inexpensive and effective method of delivery.


Most new drugs go through a phase, usually in early development, when they are administered by intravenous delivery, but many of these products end up being delivered by a different modality later, and locally acting drugs for local disease may benefit from topical administration to the epithelium, or adjacent tissue, of interest. With many of the newer medicines being proteins or peptides, oral delivery is not an option due to their degradation in the gut, so non-oral formulations are becoming even more important.


This editorial highlights some of the challenges facing developers when considering how to deliver their products. It focuses on a new route of administration that recently received approval that may represent an opportunity for non-invasive delivery of acutely needed medications.

Article Details

How to Cite
SHREWSBURY, Stephen Bevan. Trends and Advancements in Drug Delivery: What is the "perfect" method of drug delivery?. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3218>. Date accessed: 06 dec. 2022. doi: https://doi.org/10.18103/mra.v10i10.3218.
Section
Research Articles

References

1. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012;14(2):303-15

2. Liyanage PY, Hettiarichchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer 2019;1871(2):419-433

3. Cheng Z, Que H, Chen L, Sun Q, Wei X. Nanomaterial-based Drug Delivery System targeting lymph nodes. Pharmaceutics 2022;14(7):1372 doi.org/10.3390/pharmaceutics14071372

4. Daniyal M, Liu B, Wang W. Comprehensive review on graphene oxide for use in Drug Delivery System. Curr Med Chem 2020;27(22):3665-3685

5. Severino P, da Silva CF, Andrade LN, de Lima Oliviera D, Campos J, Souto EB. Alginate nanoparticles for Drug Delivery and Targeting. Curr Pharm Dev 2019:25(11):1312-1334

6. Koshkaryev A, Sawant R, Deshpande M, Torchillin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev 2013;65(1):24-35

7. Phenix CP, Togtema M, Pichardo S, Zehbe I, Curiel L. High intensity focused ultrasound technology, its scope and applications in therapy and drug delivery. J Pharm Pharm Sci 2014;17(1):136-153

8. Jain KK. An overview of Drug Delivery Systems. Methods Mol Biol 2020;2059:1-54

9. Brown JS, Gordon T, Price O, Asgharian B. Thoracic and respirable particle definitions for human health risk assessment. Part Fibre Toxicol. 2013;10:12.

10. Ruppert C, Kuchenbuch T, Schmidt S, Markart P, Gessler T, Schmehl T, Seeger W, Guenther A. Dry powder nebulization of a recombinant surfactant protein C-based surfactant for treatment of acute respiratory distress syndrome. Crit Care 2007;11(2):P208

11. Bailey CJ, Barnett AH. Why is Exubera being withdrawn? BMJ 2007;335(7630):1156. doi: 10.1136/bmj.39409.507662.94.

12. ClinicalTrials.Gov. Accessed 28 August 2022. NCT 05163717

13. Martin V, Hoekman J, Aurora SK, Shrewsbury SB. Nasal Delivery of Acute Medications for Migraine: The Upper versus Lower Nasal Space. J Clin Med 2021;10:2468 doi.org/10.3390/jcm10112468

14. Helway M, Bordoni B. Neuroanatomy, Cranial Nerve 1 (Olfactory). [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556051/

15. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: A phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) device, in healthy adult subjects. Headache 2019;59:394-409

16. Shrewsbury SB, Hocevar-Trnka J, Satterly KH, Craig KL, Lickliter JD, Hoekman J. The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults. J Clin Psychiatry 2020;81(4):12-20

17. Shrewsbury SB, Hocevar-Trnka J, Hoekman J. Drug delivery via the upper nasal space: A novel route for anesthesiologists, intensivists and emergency department physicians? J Clin Anesth Intensive Care 2021;2(1):8-14

18. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: A Phase 3, open-label study of safety, tolerability and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache 2021;61(8):1214-1226

19. Gupta S, Lee JJ, Perrin A, Khan A, Smith HJ, Farrell N, Kallogjeri D, Piccirillo JF. Efficacy and safety of saline nasal irrigation plus theophylline for treatment of COVID-19-related olfactory dysfunction: The SCENT2 phase 2 randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2022; doi: 10.1001/jamaoto.2022.1573.

20. Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 2014;124(10):2216-23

21. Aurora SK, Shrewsbury SB, Ray S, Hindiyeh N, Nguyen L. A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection. Headache 2021;61:576-589